Our Blogs

Psychotropic Drug Safety: The Role of HLA-B Variants

Understanding the Role of HLA-B in Psychiatric Medication Safety

HLA-B genes are crucial for the immune system and have implications for mental health. HLA-B is also a highly polymorphic gene, meaning it has many variants that can affect individual responses to infections, autoimmune conditions, and reactions to certain medications. Certain HLA variants, like HLA-B*15:02, are linked to severe reactions when taking certain psychiatric drugs. Genetic testing is necessary to identify these variants and prevent life-threatening side effects, especially for patients of Asian descent. 

HLA-B and Its Relevance to Mental Health

HLA-B genes are heavily involved in regulating the immune system. These genes have also been implicated in psychiatric and neurodevelopmental disorders that include schizophrenia, attention-deficit hyperactivity disorder (ADHD), and autism spectrum disorder (ASD). 

While the research here is ongoing, a strong association has been identified between HLA alleles and, specifically, depression and anxiety. This helps to explain (at least in part) the immune dysregulation that is observed in patients with psychiatric disorders. 

The HLA-B*15:02 Variant 

Psychotropic drugs are substances that have the ability to alter how the brain works, impacting a person’s mood, thoughts, feelings, awareness, and behavior. They are often used to treat mental health conditions like depression, anxiety, ADHD, and schizophrenia. Examples include antidepressants, mood stabilizers, anti-anxiety medications, anti-convulsants, stimulants, opioids, and antipsychotics. 

While these drugs are generally safe, some HLA-B gene variants can predispose people to severe side effects. The HLA-B gene influences how the immune system responds to foreign agents, including pharmaceuticals. In some individuals, specific variants, like the HLA-B15:02, can trigger an extreme immune response that may lead to serious conditions like Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). These conditions cause severe skin rashes, blistering, and peeling and can be fatal.

HLA-B15:02 is a well-known risk factor for adverse drug reactions in patients of Asian ancestry, particularly when they are prescribed carbamazepine or phenytoin. Carbamazepine is widely used for treating seizure disorders, bipolar disorder, and chronic pain. Phenytoin, an anticonvulsant, is similarly associated with these hypersensitivity reactions. This makes genetic screening for HLA-B variants an essential tool for ensuring patient safety.

Implementing HLA-B Screening in Clinical Practice

Pharmacogenomic testing can be a game-changer in reducing adverse drug reactions in psychiatric care. Testing patients for genetic variants, especially the HLA-B15:02 variant, before prescribing carbamazepine or phenytoin will allow healthcare providers to feel confident in choosing the safest medications for their patients. 

Healthcare providers should be aware of this genetic predisposition, particularly when treating patients from populations at higher risk, such as those with Asian heritage. The U.S. FDA has even included a recommendation for HLA-B testing before starting patients of Asian descent on carbamazepine due to the elevated risk of severe reactions.

Moreover, genetic testing should not be limited to carbamazepine and phenytoin. As the field of nutrigenomics and pharmacogenomics advances, more research will uncover other links between medications and genetic markers, further underscoring the importance of personalized medicine.

Summary

The HLA-B15:02 variant is a critical factor in determining a patient’s risk of severe drug reactions to medications like carbamazepine and phenytoin. By incorporating genetic testing into psychiatric care, healthcare providers can better tailor treatments to each individual, improving safety and outcomes. 

Take proactive steps to understand your patient's genetic makeup so you can improve safety and optimize therapeutic outcomes in psychiatric care. If you haven’t already integrated genetic testing into your practice, now is the time to take action.